Anika Therapeutics Insider Adds 14K Shares via RSU Grant

Rhea-AI Filing Summary

Anika Therapeutics, Inc. (ANIK) filed a Form 4 on 24 June 2025 detailing an insider equity award to director John B. Henneman III. On 20 June 2025 Mr. Henneman received 14,164 restricted stock units (RSUs) of common stock at a stated price of $0. Each RSU represents the contingent right to receive one ANIK share.

The RSUs vest in full on the earlier of the company’s 2026 annual shareholder meeting or 20 June 2026, aligning the award’s time horizon with shareholder interests over the next 12 months. Following the grant, Mr. Henneman’s total directly held beneficial ownership rises to 49,871 common shares. No derivative securities were exercised, sold, or otherwise disposed of in this filing, and no cash changed hands; the transaction is classified under code “A” (award) under SEC rules.

This appears to be a routine component of director compensation rather than an open-market purchase, yet it still modestly increases insider exposure to the stock. No other material transactions, earnings data, or financial tables were included in the filing.

Positive

• Director ownership increases by 14,164 shares, potentially aligning interests with shareholders.

Negative

• Transaction is a routine RSU grant at $0 cost, offering limited insight into insider sentiment or company fundamentals.

Insights

Corporate Governance Expert

TL;DR: Routine RSU grant boosts director ownership, neutral governance impact.

The award increases Mr. Henneman’s stake by roughly 40% of his prior holdings, improving alignment with shareholders. Vested timing within one year is consistent with typical director compensation cycles and poses minimal dilution risk given Anika’s 14 million-share float. Because it is a non-cash, service-based grant, I view the filing as governance-neutral; it neither signals insider conviction via open-market buying nor raises red flags about potential insider selling pressure.

Securities Analyst

TL;DR: Insider stake increases but no direct read-through for fundamentals.

Investors often treat insider acquisitions as bullish, yet this Form 4 reflects a standard equity retainer, not an opportunistic buy. The incremental 14,164 shares equate to about 0.10% of shares outstanding and therefore has immaterial EPS dilution. With no accompanying financial metrics or strategic commentary, the filing carries limited predictive value for near-term performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider HENNEMAN JOHN B III

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	14,164	$0.00	--

Holdings After Transaction: Common Stock — 49,871 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HENNEMAN JOHN B III

(Last) (First) (Middle)

32 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Anika Therapeutics, Inc. [ ANIK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2025		A		14,164(1)	A	$0	49,871	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026.

	/s/ John B. Henneman, III	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many restricted stock units did John B. Henneman III receive from ANIK?

He was awarded 14,164 RSUs on 20 June 2025.

When will the 14,164 RSUs granted to ANIK director John Henneman vest?

They vest on the earlier of the 2026 annual shareholder meeting or 20 June 2026.

What is John Henneman's total ANIK share ownership after this Form 4 filing?

After the award, he beneficially owns 49,871 common shares directly.

Was cash paid for the ANIK shares reported in this Form 4?

No. The RSUs were granted at a stated price of $0; no cash transaction occurred.

Does this Form 4 indicate any insider selling of ANIK stock?

No insider sales were reported; the filing only shows an award (code “A”) of RSUs.